Abstract
Transrectal ultrasound showed strong agreement with MRI results in determining the position of the inserted needles. Transrectal ultrasound is a useful tool for guided interstitial brachytherapy and is appropriate for widespread use in the treatment of locally advanced cervical cancer.
Introduction
In the treatment of locally advanced cervical cancer, standard intracavitary brachytherapy often fails to provide adequate dose distribution for large or irregularly shaped tumors. Interstitial brachytherapy, which involves the direct insertion of needles into the tumor tissue, offers a solution but requires high precision to avoid damaging adjacent organs like the bladder, rectum, or uterus.
While abdominal ultrasound is a common guidance tool, its effectiveness is often limited by patient obesity, intestinal gas, or poor posture. MRI provides superior visualization but lacks real-time capability during surgery and is prohibitively expensive for routine use in many clinical settings. This study evaluates transrectal ultrasound (TRUS)—which places the probe closer to the target—as a real-time, high-accuracy alternative for guiding needle placement.
Methods and Materials
The researchers conducted a prospective study of 48 patients (ages 35–72) with locally advanced cervical cancer. A total of 337 interstitial needles were inserted using a Utrecht applicator under the guidance of a TRT33 transrectal double-plane probe.
Following insertion, the positions of the needles were measured at seven specific sites using TRUS (labeled D1–D7). To validate these measurements, patients immediately underwent a 3.0T MRI scan. A radiologist, blinded to the ultrasound findings, performed identical measurements on the MRI images (labeled M1–M7). The degree of agreement between the two modalities was assessed using Intraclass Correlation Coefficients (ICC) and t-tests.
Key Results and Insights
The analysis revealed high concordance between TRUS and MRI measurements across all parameters. The ICC values ranged from 0.81 to 0.93, indicating "high consistency" and suggesting that TRUS is a reliable proxy for MRI in a surgical setting.
- Lateral Precision: The ICC for needle-to-cervix surface measurements (D1–D4) was particularly high (>0.90), proving TRUS is exceptionally good at determining the lateral position of needles.
- Statistical Agreement: All paired measurements (M1-D1 through M7-D7) showed p-values > 0.05, meaning there was no significant difference between the two methods.
- Depth Variance: The lowest correlation (ICC of 0.81) was found in the depth of insertion. This is likely due to the ultrasound probe slightly compressing the rectum, which subtly shifts the measurement plane compared to a static MRI.
Clinical Safety and Efficiency
The use of real-time TRUS guidance significantly enhanced procedural safety. Despite the invasive nature of interstitial brachytherapy, no instances of uterine perforation or organ damage were recorded among the 337 needle insertions. While 81.3% of patients experienced manageable post-operative pain, no major surgical errors occurred.
TRUS offers several advantages over traditional methods, including bypassing abdominal fat and gas obstacles due to its proximity to the uterus and providing immediate feedback that allows for intraoperative adjustments.
Conclusion and Future Work
Transrectal ultrasound is a reliable and accurate tool for guiding interstitial brachytherapy in advanced cervical cancer. Its high level of agreement with MRI suggests it can serve as a practical, cost-effective substitute for surgical guidance.
However, the study is limited by a small sample size and a focus on placement accuracy rather than long-term clinical outcomes. Future research is needed to determine if TRUS guidance improves long-term survival rates and to better understand the impact of tissue dynamics, such as fibrosis from previous radiation, on ultrasound clarity.
Summary updated